At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
PF-07304814 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19
In Brief
A Phase 1 clinical trial evaluating PF-07304814 and Placebo for Viral Disease. Completed, enrolled 26 participants across 13 sites in 4 countries.
Detailed Summary
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsViral Disease
CountriesBelgium, Brazil, Spain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartSep 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedSep 1, 2020
Enrollment StartSep 9, 2020
Primary CompletionJun 7, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.8 years ago
Interventions
PF-07304814drug
PF-07304814 is an anti-viral, formulated for intravenous delivery
Placebodrug
Placebo will be formulated for intravenous delivery